<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="GBP" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-13-FUND--Newton-MR_M010503_1</iati-identifier>
  <reporting-org ref="GB-GOV-13" type="10">
   <narrative xml:lang="EN">Department of Business, Energy and Industrial Strategy</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Steroid Receptors as targets for myelin regeneration by endogenous adult neural stem cells</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">The nerve fibres of the brain and spinal cord (the CNS) are surround by an insulating material called myelin that protects the fibres and allows them to carry electrical impulses very rapidly. Myelin is made by a cell called an oligodendrocyte. This cell is the primary target in several neurological diseases most notably multiple sclerosis (MS). Early in the disease the brains own stem cells are able to replace the lost oligodendrocytes and hence myelin can be restored (a regenerative process called remyelination). However, as the disease progresses and the patient ages remyelination becomes less efficient and the fibres are left without their myelin: in this state they are very vulnerable to irreversible degeneration. Therapies that enhance remyelination will have a major impact on the treatment of MS - however, none currently exist. In this project UK and Chinese laboratories will strengthen an existing collaboration to test the ability of a naturally-derived plant compound called diosgenin, which is already in clinical use, to enhance remyelination in laboratory models of MS and will continue studies to understand the mechanisms of action of diosgenin in remyelination.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The objectives of this application are:  1. To strengthen a collaboration between the Franklin/Zhao laboratory at the Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge and the He laboratory at the Second Military Medical University, Shanghai (established through the MRC UK-China Stem Cell Partnership Development Initiative) around a common interest in promoting CNS myelin regeneration by adult neural stem cells, 2. To establish the role of the alpha and beta oestrogen receptors in diosgenin-induced effects on the oligodendrocyte lineage, and the functional roles of genes whose expression is increased in oligodendrocyte lineage genes by the plant steroid diosgenin. 3. To further explore the translational and potential clinical benefits diosgenin in an autoimmune model of CNS demyelination.</narrative>
  </description>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2015-01-01" type="1"></activity-date>
  <activity-date iso-date="2015-02-01" type="2"></activity-date>
  <activity-date iso-date="2017-12-31" type="3"></activity-date>
  <activity-date iso-date="2018-01-31" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">UK Research &amp; Innovation</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">International Development</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Newton</narrative>
   </person-name>
   <email>gcrf@ukri.org</email>
   <website>https://www.ukri.org/</website>
   <mailing-address>
    <narrative xml:lang="EN">Polaris House, Swindon, SN2 1LF</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country percentage="100">
   <narrative xml:lang="EN">China (People&apos;s Republic of)</narrative>
  </recipient-country>
  <recipient-region code="789" percentage="100" vocabulary="FAR EAST ASIA, REGIONAL"></recipient-region>
  <sector code="43082" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Research/scientific institutions</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="2" type="1">
   <period-start iso-date="2014-04-01"></period-start>
   <period-end iso-date="2014-03-31"></period-end>
   <value currency="GBP" value-date="2014-11-17">26358.81</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2015-04-01"></period-start>
   <period-end iso-date="2015-03-31"></period-end>
   <value currency="GBP" value-date="2014-11-17">105648.74</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2016-04-01"></period-start>
   <period-end iso-date="2016-03-31"></period-end>
   <value currency="GBP" value-date="2014-11-17">106504.48</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2017-04-01"></period-start>
   <period-end iso-date="2017-03-31"></period-end>
   <value currency="GBP" value-date="2014-11-17">53575.1</value>
  </budget>
  <capital-spend percentage="0"></capital-spend>
  <document-link format="APPLICATION/PDF" url="https://www.ukri.org/funding/information-for-award-holders/grant-terms-and-conditions/">
   <title>
    <narrative xml:lang="EN">UK Research &amp; Innovation Grant Terms and Conditions</narrative>
   </title>
   <category code="A04"></category>
  </document-link>
  <conditions attached="1"></conditions>
  <iati-activities>
   <iati-activity>
    <title>
     <narrative xml:lang="EN"></narrative>
    </title>
   </iati-activity>
  </iati-activities>
 </iati-activity>
</iati-activities>
